Enveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth Conference
22 February 2023 - 11:33PM
Business Wire
CEO Joseph Tucker, Ph.D., to deliver company
presentation and participate in panel discussion
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),
a biotechnology company dedicated to the development of novel
small-molecule therapeutics for the treatment of anxiety,
depression, and addiction disorders, today announced that Joseph
Tucker, Ph.D., Chief Executive Officer, will present at the
Gravitas Securities Inc. 6th Annual Growth Conference being held
Thursday, March 2, 2023, at the Fairmont Pacific Rim Hotel in
Vancouver, British Columbia.
Details of the presentations are as follows:
Presentation Format:
Healthcare Panel
Date:
Thursday, March 2, 2023
Time:
1:40 p.m. PST
Location:
Fairmont Pacific Rim Hotel
Presentation Format:
Company Presentation
Date:
Thursday, March 2, 2023
Time:
2:00 p.m. PST
Location:
Sapphire Ballroom, Fairmont Pacific Rim
Hotel
During the conference, Dr. Tucker will host individual
one-on-one meetings with registered investors, showcasing Enveric’s
business and clinical development strategy, recent corporate
achievements, and anticipated milestones.
About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company
dedicated to the development of novel small-molecule therapeutics
for the treatment of anxiety, depression, and addiction disorders.
Leveraging its unique discovery and development platform, The
Psybrary™, Enveric has created a robust Intellectual Property
portfolio of New Chemical Entities for specific mental health
indications. Enveric’s lead program, the EVM201 Series, comprises
next generation synthetic psilocybin analogues that are considered
prodrugs of the active metabolite, psilocin. Enveric is developing
the first product from the EVM201 Series – EB-373 – for the
treatment of anxiety disorders. Enveric is also advancing its third
generation of therapeutics, the EVM301 Series, to offer a holistic
approach for treating central nervous system disorders. Enveric is
headquartered in Naples, FL with offices in Cambridge, MA and
Calgary, AB Canada. For more information, please visit
www.enveric.com.
Forward-Looking Statements
This press release contains forward-looking statements and
forward-looking information within the meaning of applicable
securities laws. These statements relate to future events or future
performance. All statements other than statements of historical
fact may be forward-looking statements or information. Generally,
forward-looking statements and information may be identified by the
use of forward-looking terminology such as “plans,”” expects” or
“does not expect,” “proposed,” “is expected,” “budgets,”
“scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or
“does not anticipate,” or “believes,” or variations of such words
and phrases, or by the use of words or phrases which state that
certain actions, events or results may, could, would, or might
occur or be achieved. Forward-looking statements consist of not
purely historical statements, including any statements regarding
beliefs, plans, expectations, or intentions regarding the future.
Such forward-looking statements are based on the beliefs of
management as well as assumptions made by and information currently
available to management. Actual results could differ materially
from those contemplated by the forward-looking statements as a
result of certain factors, including, but not limited to, the
ability of Enveric to successfully spin-off its cannabinoid assets;
the ability to achieve the value creation contemplated by technical
developments; the impact of the novel coronavirus (COVID-19) on
Enveric’s ongoing and planned clinical trials; the geographic,
social and economic impact of COVID-19 on Enveric’s ability to
conduct its business and raise capital in the future when needed;
delays in planned clinical trials; the ability to establish that
potential products are efficacious or safe in preclinical or
clinical trials; the ability to establish or maintain
collaborations on the development of therapeutic candidates; the
ability to obtain appropriate or necessary governmental approvals
to market potential products; the ability to obtain future funding
for developmental products and working capital and to obtain such
funding on commercially reasonable terms; Enveric’s ability to
manufacture product candidates on a commercial scale or in
collaborations with third parties; changes in the size and nature
of competitors; the ability to retain key executives and
scientists; and the ability to secure and enforce legal rights
related to Enveric’s products, including patent protection. A
discussion of these and other factors, including risks and
uncertainties with respect to Enveric, is set forth in Enveric’s
filings with the Securities and Exchange Commission (SEC),
including Enveric’s Annual Report on Form 10-K and its Quarterly
Reports on Form 10-Q. Enveric disclaims any intention or obligation
to revise any forward-looking statements, whether as a result of
new information, future events or otherwise, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230222005518/en/
Investor Relations Tiberend Strategic Advisors, Inc.
Daniel Kontoh-Boateng (862) 213-1398
dboateng@tiberend.com
Media Relations Tiberend Strategic Advisors, Inc. Casey
McDonald (646) 577-8520 cmcdonald@tiberend.com
Enveric Biosciences (NASDAQ:ENVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enveric Biosciences (NASDAQ:ENVB)
Historical Stock Chart
From Apr 2023 to Apr 2024